| Literature DB >> 27213326 |
Elena Pahonțu1, Codruța Paraschivescu2, Diana-Carolina Ilieș3, Donald Poirier4, Camelia Oprean5, Virgil Păunescu6, Aurelian Gulea7, Tudor Roșu8, Ovidiu Bratu9.
Abstract
New Cu(II), Pd(II) and Pt(II) complexes, (Cu(L)(H₂O)₂(OAc)) (1), (Cu(HL)(H₂O)₂(SO₄)) (2), (Cu(L)(H₂O)₂(NO₃)) (3), (Cu(L)(H₂O)₂(ClO₄)) (4), (Cu(L)₂(H₂O)₂) (5), (Pd(L)(OAc))H₂O (6), and (Pt(L)₂) (7) were synthesized from 8-ethyl-2-hydroxytricyclo(7.3.1.0(2,7))tridecan-13-one thiosemicarbazone (HL). The ligand and its metal complexes were characterized by IR, ¹H-NMR, (13)C-NMR, UV-Vis, FAB, EPR, mass spectroscopy, elemental and thermal analysis, magnetic susceptibility measurements and molar electric conductivity. The free ligand and the metal complexes have been tested for their antimicrobial activity against E. coli, S. enteritidis, S. aureus, E. faecalis, C. albicans and cytotoxicity against the NCI-H1573 lung adenocarcinoma, SKBR-3 human breast, MCF-7 human breast, A375 human melanoma and HL-60 human promyelocytic leukemia cell lines. Copper complex 2 exhibited the best antiproliferative activities against MCF-7 human breast cancer cells. A significant inhibition of malignant HL-60 cell growth was observed for copper complex 2, palladium complex 6 and platinum complex 7, with IC50 values of 1.6 µM, 6.5 µM and 6.4 µM, respectively.Entities:
Keywords: A375 human melanoma cells; HL-60 leukemia cells; MCF-7; NCI-H1573 lung adenocarcinoma cells; SKBR-3 human breast cancer cells; antimicrobial activity; copper(II); palladium(II) and platinum(II) complexes
Mesh:
Substances:
Year: 2016 PMID: 27213326 PMCID: PMC6273217 DOI: 10.3390/molecules21050674
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of the ligand 8-ethyl-2-hydroxytricyclo(7.3.1.02,7)tridecan-13-one-thio-semicarbazone (HL).
Figure 1Proposed structures of the newly obtained metal complexes 1–7.
Electronic spectra (cm−1) and magnetic moment (BM) of the complexes 1–7.
| Metal Complex Molecular Formula | Transitions d–d (cm−1) | µeff (BM) | Geometry | ||
|---|---|---|---|---|---|
| (Cu(L)(H2O)2(OAc)) ( | 2B1g→2A1g - | 2B1g→2B2g 13,570 | 2B1g→2Eg 20,000 | 1.99 | Octahedral distorted |
| (Cu(HL)(H2O)2(SO4)) ( | 2B1g→2A1g - | 2B1g→2B2g 13,570 | 2B1g→2Eg 20,000 | 1.83 | Octahedral distorted |
| (Cu(L)(H2O)2(NO3)) ( | 2B1g→2A1g - | 2B1g→2B2g 12,690 | 2B1g→2Eg 20,000 | 1.69 | Square-pyramidal |
| (Cu(L)(H2O)2(ClO4)) ( | 2B1g→2A1g - | 2B1g→2B2g 13,570 | 2B1g→2Eg 20,100 | 1.88 | Octahedral distorted |
| (Cu(L)2(H2O)2) ( | 2B1g→2A1g - | 2B1g→2B2g 12,550 | 2B1g→2Eg 20,000 | 1.97 | Octahedral distorted |
| (Pd(L)(OAc))(H2O) ( | 1A1g→1B1g - | 1A1g→1A2g 22,220 | 1A1g→1Eg - | * | Square-planar |
| (Pt(L)2) ( | 1A1g→1B1g - | 1A1g→1A2g 23,250 | 1A1g→1Eg - | * | Square-planar |
* diamagnetic.
EPR spectral parameters of the Cu(II) complexes 1–5.
| 1 | 2 | 3 | 4 | 5 | |
|---|---|---|---|---|---|
| Polycrystalline (298 K) | |||||
| g// | 2.404 | 2.371 | 2.208 | 2.409 (g3) | 2.237 |
| g⊥ | 2.087 | 2.103 | 2.041 | 2.193 (g2) | 2.065 |
| 2.011 (g1) | |||||
| DMSO (77K) | |||||
| g// | 2.394 | 2.400 | 2.399 | 2.399 | 2.400 |
| g⊥ | 2.082 | 2.088 | 2.076 | 2.078 | 2.098 |
| A// | 117.4 | 118.0 | 119.2 | 118.0 | 119.0 |
| α2 | 0.789 | 0.838 | 0.802 | 0.792 | 0.831 |
| β2 | 0.989 | 0.998 | 0.890 | 0.996 | 0.978 |
| δ2 | 0.992 | 0.879 | 0.973 | 0.969 | 0.952 |
| K// | 0.780 | 0.841 | 0.717 | 0.769 | 0.787 |
| K⊥ | 0.791 | 0.569 | 0.785 | 0.758 | 0.753 |
Figure 2EPR spectra of complexes 1–5 in the polycrystalline state at 298 K.
Figure 3EPR spectrum of complex 5 in the state at 298 K and 77 K.
Figure 4EPR spectra of complexes 1–5 in DMSO solution (a) at 298 K; (b) second derivative spectra.
Figure 5EPR spectra of complexes 1–5 in DMSO solution at 77 K.
Antibacterial and antifungal activities of ligand (HL) and complexes 1–7 as MIC a/MBC b values (mg/mL).
| Compounds |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
| C16H27N3OS ( | 0.5 | >10.0 | >10.0 | >10.0 | 0.5 | >10.0 | >10.0 | >10.0 | 0.5 | >10.0 |
| (Cu(L)(H2O)2(OAc)) ( | >10.0 | >10.0 | 0.5 | >10.0 | >10.0 | >10.0 | >10.0 | >10.0 | >10.0 | >10.0 |
| (Cu(HL)(H2O)2(SO4)) ( | 0.25 | >10.0 | 0.25 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| (Cu(L)(H2O)2(NO3)) ( | >10.0 | >10.0 | >10.0 | >10.0 | 0.12 | 0.25 | 0.12 | 0.12 | 0.5 | 0.5 |
| (Cu(L)(H2O)2(ClO4)) ( | 0.5 | >10.0 | 0.5 | >10.0 | 0.12 | >10.0 | 0.12 | >10.0 | 0.12 | 0.12 |
| (Cu(L)2(H2O)2) ( | >10.0 | >10.0 | 0.5 | >10.0 | 0.12 | >10.0 | 0.12 | >10.0 | 0.12 | 0.12 |
| (Pd(L)(OAc))(H2O) ( | >10.0 | >10.0 | 0.5 | >10.0 | 0.5 | >10.0 | >10.0 | >10.0 | >0.5 | >0.5 |
| (Pt(L)2) ( | >10.0 | >10.0 | 0.5 | >10.0 | >10.0 | >10.0 | 0.12 | >10.0 | >10.0 | >10.0 |
| Cu(OAc)2·H2O | 0.5 | - | 1.024 | - | 1.024 | - | 0.5 | - | - | - |
| CuSO4·5H2O | 0.5 | - | 1.024 | - | 0.5 | - | 0.5 | - | 1.024 | - |
| Cu(NO3)2·3 H2O | 1.024 | - | 1.024 | - | 1.024 | - | 1.024 | - | - | - |
| Cu(ClO4)2·6 H2O | 1.024 | - | 1.024 | - | 1.024 | - | 0.5 | - | - | |
| CuCl2·2H2O | 1.024 | - | 0.5 | - | 0.5 | - | 0.5 | - | - | - |
| Pd(OAc)2 | 1.024 | - | 1.024 | - | 1.024 | - | 0.5 | - | - | |
| K2(PtCl4) | 1.024 | - | 1.024 | - | 1.024 | - | 0.5 | - | - | |
| Furacillinum | 0.018 | 0.037 | 0.009 | 0.009 | 0.009 | 0.009 | 0.037 | 0.037 | - | - |
| Nystatine | - | - | - | - | - | - | - | - | 0.08 | 0.08 |
E. coli (Escherichia coli, ATCC 25922); S. enteritidis (Salmonella enteritidis); S. aureus (Staphylococcus aureus, ATCC 25923); E. faecalis (Enterococcus faecalis); C. albicans (Candida albicans). a MIC–minimum inhibitory concentration. b MBC—minimum bactericide concentration. G(−): Gram-negative bacteria; G(+): Gram-positive bacteria.
Figure 6The effects of ligand HL and complexes 1–7 on SKBR-3, MCF-7, A375, NCI-H1573 and HL-60 cell proliferation. (a) Inhibition of cell proliferation on SKBR-3 human breast cancer cell line; (b) Inhibition of cell proliferation on MCF-7 human breast cancer cell line; (c) Inhibition of cell proliferation on A375 melanoma cell line; (d) Inhibition of cell proliferation on NCI-H1573 lung adenocarcinoma cell line; (e) Inhibition of cell proliferation on human leukemia HL-60 cells after exposure to 10 µM of tested compounds.
Antiproliferative activity of ligand and metal complexes on human leukemia HL-60 cells at three concentrations a.
| Compound | Inhibition of Cell Proliferation % | IC50 (µM) b | ||
|---|---|---|---|---|
| 10 µM | 1 µM | 0.1 µM | ||
| C16H27N3OS ( | −2.90 | −5.72 | 0.31 | - |
| (Cu(L)(H2O)2(OAc)) ( | 21.97 | −2.11 | −2.58 | ≥10 |
| (Cu(HL)(H2O)2(SO4)) ( | 100.00 | 5.14 | -5.25 | 1.6 ± 3 |
| (Cu(L)(H2O)2(NO3)) ( | 63.91 | 8.12 | 1.35 | 6.4 ± 5 |
| (Cu(L)(H2O)2(ClO4)) ( | 48.94 | 6.48 | 1.13 | 6.5 ± 4 |
| (Cu(L)2(H2O)2) ( | 43.43 | 8.73 | 7.20 | 14.2 ± 3 |
| (Pd(L)(OAc))(H2O) ( | 100.00 | −22.99 | −3.85 | 6.5 ± 4 |
| (Pt(L)2) ( | 100.00 | −10.32 | −8.13 | 6.4 ± 2 |
| DOXO c | 91.94 | 94.55 | 77.00 | ≤0.1 |
a SEM < ± 4% of a single experiment in triplicate. b The IC50 value was defined as the concentration at which 50% survival of cells was observed. c DOXO (doxorubicin) used as a positive control.